[1]
|
Hiltunen, T.P., Donner, K.M., Sarin, A.P., Saarela, J., Ripatti, S., Chapman, A.B., Gums, J.G., Gong, Y., Cooper-DeHoffff, R.M., Frau, F., et al. (2015) Pharmacogenomics of Hypertension: A Genome-Wide, Place-bo-Controlled Cross-Over Study, Using Four Classes of Antihypertensive Drugs. Journal of the American Heart Asso-ciation, 4, e001521.
https://doi.org/10.1161/JAHA.114.001521
|
[2]
|
Padmanabhan, S., Newton-Cheh, C. and Dominiczak, A. (2012) Genetic Basis of Blood Pressure and Hypertension. Trends in Genetics, 28, 397-408. https://doi.org/10.1016/j.tig.2012.04.001
|
[3]
|
Ehret, G.B. and Caulfield, M.J. (2013) Genes for Blood Pressure: An Opportunity to Understand Hypertension. European Heart Journal, 34, 951-961. https://doi.org/10.1093/eurheartj/ehs455
|
[4]
|
Munroe, P.B., Barnes, M.R. and Caulfield, M.J. (2013) Advances in Blood Pressure Genomics. Circulation Research, 112, 1365-1379. https://doi.org/10.1161/CIRCRESAHA.112.300387
|
[5]
|
刘力生, 吴兆苏, 王文, 等. 中国高血压防治指南2018年修订版[J]. 心脑血管病防治, 2019, 19(1): 6-49.
|
[6]
|
Yasar, Ü., Forslund-Bergengren, C., Tybring, G., et al. (2002) Pharmacokinetics of Losartan and Its Metabolite E-3174 in Relation to the CYP2C9 Genotype. Clinical Pharma-cology & Therapeutics, 71, 89-98.
https://doi.org/10.1067/mcp.2002.121216
|
[7]
|
Yasar, Ü., Tybring, G., Hidestrand, M., et al. (2001) Role of CYP2C9 Polymorphism in Losartan Oxidation. Drug Metabolism and Disposition, 29, 1051-1056.
|
[8]
|
Garimella, P.S., du Toit, C., Le, N.N. and Padmanabhan, S. (2023) A Genomic Deep Field View of Hypertension. Kidney International, 103, 42-52. https://doi.org/10.1016/j.kint.2022.09.029
|
[9]
|
Lifton, R.P., Gharavi, A.G. and Geller, D.S. (2001) Molecular Mechanisms of Human Hypertension. Cell, 104, 545-556.
https://doi.org/10.1016/S0092-8674(01)00241-0
|
[10]
|
Pazoki, R., Dehghan, A., Evangelou, E., et al. (2018) Genetic Predisposition to High Blood Pressure and Lifestyle Factors: Associations with Midlife Blood Pressure Levels and Car-diovascular Events. Circulation, 137, 653-661.
https://doi.org/10.1161/CIRCULATIONAHA.117.030898
|
[11]
|
Giri, A., Hellwege, J.N., Keaton, J.M., et al. (2019) Trans-Ethnic Association Study of Blood Pressure Determinants in over 750, 000 Individuals. Nature Genetics, 51, 51-62. https://doi.org/10.1038/s41588-018-0303-9
|
[12]
|
Surendran, P., Feofanova, E.V., Lahrouchi, N., et al. (2020) Discovery of Rare Variants Associated with Blood Pressure Regulation through Meta-Analysis of 1.3 Million Individu-als. Nature Genetics, 52, 1314-1332.
https://doi.org/10.1038/s41588-020-00713-x
|
[13]
|
Sakaue, S., Kanai, M., Tanigawa, Y., et al. (2021) A Cross-Population Atlas of Genetic Associations for 220 Human Phenotypes. Nature Genetics, 53, 1415-1424. https://doi.org/10.1038/s41588-021-00931-x
|
[14]
|
Backman, J.D., Li, A.H., Marcketta, A., et al. (2021) Exome Sequencing and Analysis of 454,787 UK Biobank Participants. Nature, 599, 628-634. https://doi.org/10.1038/s41586-021-04103-z
|
[15]
|
Padmanabhan, S. and Dominiczak, A.F. (2021) Genomics of Hypertension: The Road to Precision Medicine. Nature Reviews Cardiology, 18, 235-250. https://doi.org/10.1038/s41569-020-00466-4
|
[16]
|
Torkamani, A., Wineinger, N.E. and Topol, E.J. (2018) The Personal and Clinical Utility of Polygenic Risk Scores. Nature Reviews Cardiology, 19, 581-590. https://doi.org/10.1038/s41576-018-0018-x
|
[17]
|
Loos, R.J. (2011) Genetics: Genome-Wide Risk Profiles—Will They Change Your Life (Style)? Nature Reviews Endocrinology, 7, 252-254. https://doi.org/10.1038/nrendo.2011.41
|
[18]
|
Torrellas, C., Carril, J.C. and Cacabelos, R. (2014) Benefits of Phar-macogenetics in the Management of Hypertension. Journal of Pharmacogenomics & Pharmacoproteomics, 5, Article ID: 1000126.
https://doi.org/10.4172/2153-0645.1000126
|
[19]
|
Cacabelos, R. (2012) The Metabolomic Paradigm of Phar-macogenomics in Complex Disorders. Metabolomics, 2, e119.
https://doi.org/10.4172/2153-0769.1000e119
|
[20]
|
Cooper-DeHoff, R.M. and Johnson, J.A. (2016) Hypertension Pharmacogenomics: In Search of Personalized Treatment Approaches. Nature Reviews Nephrology, 12, 110-122. https://doi.org/10.1038/nrneph.2015.176
|
[21]
|
Ye, Y., Kuhn, C., Kösters, M., et al. (2019) Anti α-Enolase Antibody Is a Novel Autoimmune Biomarker for Unexplained Recurrent Miscarriages. EBioMedicine, 41, 610-622. https://doi.org/10.1016/j.ebiom.2019.02.027
|
[22]
|
冯星, 高超, 杨柏松, 康效嘉, 刘晓梅. 性别因素对吉林地区满族人抗高血压药物基因多态性的影响[J]. 中国地方病防治, 2020, 35(4): 480-482.
|
[23]
|
孙思雨, 尚茂林. 蚌埠地区高血压病人药物基因多态性的分布[J]. 蚌埠医学院学报, 2022, 47(7): 912-916.
https://doi.org/10.13898/j.cnki.issn.1000-2200.2022.07.018
|
[24]
|
王申, 张舜华, 薛薇, 王鹏飞, 任格, 陈传军. 沙坦类药物代谢酶CYP2C9的基因遗传多态性在高血压患者中的分布特征[J]. 中国循证心血管医学杂志, 2021, 13(6): 712-715.
|
[25]
|
易珍奎. 286例高血压患者的抗高血压药物相关基因多态性分析[J]. 中国处方药, 2022, 20(4): 47-48.
|
[26]
|
邓明影, 冯晓俊, 沈爱宗, 张蕾. 安徽地区高血压药物基因多态性分布与降压药个体化应用分析[J]. 中国医院药学杂志, 2022, 42(8): 827-831. https://doi.org/10.13286/j.1001-5213.2022.08.12
|
[27]
|
陈盈, 杨晓燕, 张金山, 陈连华, 石红. 降压药物相关基因多态性在肥城地区高血压人群中的分布研究[J]. 心血管病防治知识, 2021, 11(33): 20-24.
|
[28]
|
喻晶, 杨璐, 张舒琼, 王秋, 姜航. 7个高血压药物相关基因的多态性在582例汉族高血压患者中的分布[J]. 国际检验医学杂志, 2021, 42(3): 325-328+333.
|
[29]
|
高菊英, 刘丽宏, 万子睿, 李润堂, 田艳, 赵娜, 赵辉, 邓丽梅, 柴佳星, 王淑玲, 孙莉. 抗高血压药物基因多态性对呼伦贝尔地区三少民族高血压患者个体化治疗方案的参考价值[J]. 中国药物应用与监测, 2022, 19(3): 145-149.
|
[30]
|
李柳, 王亚茹, 张娣, 陈勤聪, 王明, 王硕. 高血压个体化用药基因检测在Ⅲ级高血压患者中的应用[J]. 昆明医科大学学报, 2022, 43(4): 112-117.
|
[31]
|
肖智林, 楚志文, 杨梅, 谢秀梅, 陈美芳. 药物基因组学导向高血压个体化用药的临床研究[J]. 中国实用内科杂志, 2020, 40(10): 850-854. https://doi.org/10.19538/j.nk2020100113
|
[32]
|
Xiao, Z.-L., Yang, M., Chen, X.-B., Xie, X.-M. and Chen, M.-F. (2022) Personalized Antihypertensive Treatment Guided by Phar-macogenomics in China. Cardiovascular Diagnosis and Therapy, 12, 635-645.
https://doi.org/10.21037/cdt-22-154
|
[33]
|
李晨瑜. 药物基因组学对唐山地区高血压人群降压疗效的影响[D]: [硕士学位论文]. 石家庄: 河北医科大学, 2022. https://doi.org/10.27111/d.cnki.ghyku.2022.001056
|
[34]
|
Beitelshees, A.L., Gong, Y., Wang, D., Schork, N.J., Cooper-Dehoff, R.M., Langaee, T.Y., Shriver, M.D., Sadee, W., Knot, H.J., Pepine, C.J., et al. (2007) KCNMB1 Geno-type Influences Response to Verapamil SR and Adverse Outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST). Pharmacogenetics and Genomics, 17, 719-729.
https://doi.org/10.1097/FPC.0b013e32810f2e3c
|